EMA Authorised: Lamivudine Teva (lamivudine) — Teva B.V.

View source ↗

Summary

The EMA authorised Lamivudine Teva (lamivudine) for chronic hepatitis B. Teva B.V. is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Lamivudine Teva (lamivudine)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B, Chronic. MAH: Teva B.V.. Decision date: 06/06/2024